Impact of statin use on cancer recurrence and mortality in breast cancer: A systematic review and meta‐analysis
The DOI matches its Crossref record; 5 of the 5 references it cites were found in a registry or an index.
Abstract
Statins have shown antineoplastic properties in preclinical studies with breast cancer cells. They inhibit the enzyme “HMG CoA reductase” and the expression of this enzyme in cancer cells has been implicated as a favorable prognostic factor in patients with breast cancer. After a search of MEDLINE and Embase from inception through November 2015, 817 abstracts were reviewed to identify studies that described an association between statin use and outcomes in breast cancer. A total of 14 studies which included 75,684 women were identified. In a meta‐analysis of 10 studies, statin use was associated with improved recurrence‐free survival (RFS; HR 0.64; 95% CI 0.53–0.79, I2 = 44%). Furthermore, this RFS benefit appeared to be confined to use of lipophilic statins (HR 0.72; 95% CI 0.59–0.89) as hydrophilic statin use was not associated with improvement in RFS (HR 0.80; 95% CI 0.44–1.46). Statin users similarly showed improved overall survival in a meta‐analysis with substantial heterogeneity (8 studies, HR 0.66; 95% CI 0.44–0.99, I2 = 89%). Statin users also had improved cancer‐specific survival, although this relationship was measured with less precision (six studies, HR 0.70; 95% CI 0.46–1.06, I2 = 86%). In conclusion, breast cancer patients who use statins, or specifically, lipophilic statins show improved recurrence‐free survival. Statin users also had improved overall survival and cancer‐specific survival. These findings should be assessed in a prospective randomized cohort and the choice of statin, dose and biomarkers that may predict the efficacy of these drugs should be identified.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
GRADE guidelines: 7. Rating the quality of evidence—inconsistency
Guyatt, G. H., Oxman, A. D., Kunz, R., Woodcock, J., Brozek, J., Helfand, M., Alonso-Coello, P., Glasziou, P., Jaeschke, R., Akl, E. A., et al. (2011) · Journal of Clinical Epidemiology · doi:10.1016/j.jclinepi.2011.03.017 · Cited by 2,320
Triple-negative breast cancer: epidemiological considerations and recommendations
Boyle, P. (2012) · Annals of Oncology · doi:10.1093/annonc/mds187 · Cited by 593
Statin Prescriptions and Breast Cancer Recurrence Risk: A Danish Nationwide Prospective Cohort Study
Ahern, T. P., Pedersen, L., Tarp, M., Cronin-Fenton, D. P., Garne, J. P., Silliman, R. A., Sorensen, H. T., & Lash, T. L. (2011) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djr291 · Cited by 387
Targeting HMG-CoA reductase with statins in a window-of-opportunity breast cancer trial
Bjarnadottir, O., Romero, Q., Bendahl, P.-O., Jirström, K., Rydén, L., Loman, N., Uhlén, M., Johannesson, H., Rose, C., Grabau, D., et al. (2013) · Breast Cancer Research and Treatment · doi:10.1007/s10549-013-2473-6 · Cited by 230
Kwan, M. L., Habel, L. A., Flick, E. D., Quesenberry, C. P., & Caan, B. (2008) · Breast Cancer Research and Treatment · doi:10.1007/s10549-007-9683-8 · Cited by 175
Cited by
p53 Represses the Mevalonate Pathway to Mediate Tumor Suppression
Moon, S.-H., Huang, C.-H., Houlihan, S. L., Regunath, K., Freed-Pastor, W. A., Morris, J. P., Tschaharganeh, D. F., Kastenhuber, E. R., Barsotti, A. M., Culp-Hill, R., et al. (2019) · Cell · doi:10.1016/j.cell.2018.11.011 · Cited by 435
Liu, W., Chakraborty, B., Safi, R., Kazmin, D., Chang, C.-Y., & McDonnell, D. P. (2021) · Nature Communications · doi:10.1038/s41467-021-25354-4 · Cited by 341
Obesity, Type 2 Diabetes, and Cancer Risk
Scully, T., Ettela, A., LeRoith, D., & Gallagher, E. J. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2020.615375 · Cited by 256
Association of statin use with clinical outcomes in patients with triple‐negative breast cancer
Nowakowska, M. K., Lei, X., Thompson, M. T., Shaitelman, S. F., Wehner, M. R., Woodward, W. A., Giordano, S. H., & Nead, K. T. (2021) · Cancer · doi:10.1002/cncr.33797 · Cited by 62
“Statins are among the most widely prescribed drug classes in the United States and may have beneficial effects in the treatment and prevention of cancer.(1,2) Statins reduce cholesterol levels by inhibiting the rate- limiting step in the mevalonate pathway, which has been shown to be upregulated in several cancer type…”
BackgroundStatin use after cancer diagnosis and survival among patients with cancer
Guo, H., Malone, K. E., Heckbert, S. R., & Li, C. I. (2025) · Cancer Causes & Control · doi:10.1007/s10552-024-01939-4 · Cited by 4
“Consistent with the in vitro evidence, many observational studies suggest a reduction of cancer-specific mortality associated with statin use in a number of cancers, including breast cancer [5, 6], colorectal cancer [7], lung cancer [8], prostate cancer [9], and pancreatic cancer [10].”
Metadata
- Authors
- Manthravadi, S., Shrestha, A., & Madhusudhana, S.
- Venue
- International Journal of Cancer
- Publisher
- Wiley
- Published
- 2016-05-31
- Volume
- 139
- Issue
- 6
- Pages
- 1281-1288
- ISSN
- 0020-7136 (ISSN-L)
- 1097-0215
- OpenAlex
- W2380844943
- Cited by
- 142
- References
- 5
- FWCI
- 1.14
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.